Ipsen is a global specialty-driven pharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.
Ipsen at a glance
Ipsen is a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience and Rare Diseases. We also have a well-established and successful Consumer Healthcare business. We are committed to discovering new solutions for targeting debilitating diseases and improving the quality of life for patients.
Since it was founded in 1929, by Henri Beaufour, Ipsen has developed, and made available to patients, a number of products in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare. Global footprint, acquisitions, partnerships, scientific collaborations and innovations: learn about the development of our group over the years.
Learn more about the Ipsen Group governance: board of directors, senior management, compensation of corporate officers, securities transactions and company by-laws.
Our strategy is to build a global biopharma company focused on innovation and specialty care which delivers differentiated therapeutics to meet unmet patient needs. Our biotech mindset – combined with the scale and advantages of a global biopharmaceutical company – has already established us as a development and commercial powerhouse in our core focused areas, with a proven ability to bring new, life changing therapies to market.
The Ipsen Group’s medicines are used in over 115 countries across the globe. Our extensive and diversified geographic footprint allows us to meet the needs of patients at our commercial operations sites, industrial sites and R&D centers: Discover our Group’s locations on the interactive map.